We postulate that multiple apoptototic events are indusce through testosterone depletion and repletion with taxotere given in conjunction with androgen withdrawal.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
102
Leuprolide LUPRON
Starting during week 3 (day 19) of cycle 1, 7.5G applied topically daily for 3 days (applied at approximately 9p)
70 mg/m2 given on day o1 of each 3 week cycle
Memorial Sloan Kettering Cancer Center
New York, New York, United States
PSA of <_ 0.05 ng/ml After Radical Prostatectomy or Radiation Therapy and PSA <_ 2.0 ng/ml for Patients With Clinical Metastases Without Prior Definitive Therapy
Time frame: Conclusion of the study (at 6 months then at 18 months post-treatment)
The Effects of Testosterone Administration on Docetaxel Pharmacokinetics.
Docetaxel Pharmacokinetic parameters for cycles 1 and 2.
Time frame: at Cycle 1 and 2
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.